Real-world evidence supports CAR-T-cell therapy’s safety and efficacy
12 August 2022
- A retrospective study in 275 (treated) patients with relapsed or refractory large B-cell lymphoma found (Yescarta) axicabtagene ciloleucel gave similar responses to those seen in clinical trials
- This evidence is valuable in supporting the clinical trial results; because “The issue with clinical trials is that they often are very highly selective,” – Michael D. Jain, MD, PhD; Moffitt Cancer Center
- “Our work is important because it shows that even those patients who don’t strictly adhere to clinical trial inclusion and exclusion criteria can still benefit from this therapy,” – Michael D. Jain
- These real-world results should give clinicians confidence with prescribing the CAR-T, especially for patients who do not fall under the clinical trial criteria